mRNA Cancer Vaccines Therapeutics Market

ID: MRFR/HC/30711-HCR
128 Pages
Rahul Gotadki
Last Updated: May 15, 2026
mRNA Cancer Vaccines And Therapeutics Market Research Report By Technology (Self-Amplifying mRNA, Non-Self-Amplifying mRNA, Lipid Nanoparticle (LNP) Encapsulation), By Application (Preventive Vaccines, Therapeutic Vaccines, Combination Therapies), By Cancer Type (Melanoma, Breast Cancer, Lung Cancer, Prostate Cancer), By Route of Administration (Intramuscular, Intravenous, Subcutaneous), By Patient Demographics (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
mRNA Cancer Vaccines Therapeutics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)18.12%
2024 Market Size$ 6.25 Billion
2025 Market Size$ 7.38 Billion
2035 Market Size$ 39.01 Billion
Key Players
Moderna
BioNTech
Pfizer
CureVac
Translate Bio
Gritstone Oncology
Trends
  • Personalized Medicine Focus
  • Regulatory Adaptations
  • Immunotherapy Integration
Opportunities
  • Rising Incidence of Cancer
  • Advancements in mRNA Technology
  • Growing Investment in Cancer Research
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Technology (USD Billion)
      1. 4.1.1 Self-Amplifying mRNA
      2. 4.1.2 Non-Self-Amplifying mRNA
      3. 4.1.3 Lipid Nanoparticle (LNP) Encapsulation
    2. 4.2 Healthcare, BY Application (USD Billion)
      1. 4.2.1 Preventive Vaccines
      2. 4.2.2 Therapeutic Vaccines
      3. 4.2.3 Combination Therapies
    3. 4.3 Healthcare, BY Cancer Type (USD Billion)
      1. 4.3.1 Melanoma
      2. 4.3.2 Breast Cancer
      3. 4.3.3 Lung Cancer
      4. 4.3.4 Prostate Cancer
    4. 4.4 Healthcare, BY Route of Administration (USD Billion)
      1. 4.4.1 Intramuscular
      2. 4.4.2 Intravenous
      3. 4.4.3 Subcutaneous
    5. 4.5 Healthcare, BY Patient Demographics (USD Billion)
      1. 4.5.1 Pediatric
      2. 4.5.2 Adult
      3. 4.5.3 Geriatric
    6. 4.6 Healthcare, BY Region (USD Billion)
      1. 4.6.1 North America
        1. 4.6.1.1 US
        2. 4.6.1.2 Canada
      2. 4.6.2 Europe
        1. 4.6.2.1 Germany
        2. 4.6.2.2 UK
        3. 4.6.2.3 France
        4. 4.6.2.4 Russia
        5. 4.6.2.5 Italy
        6. 4.6.2.6 Spain
        7. 4.6.2.7 Rest of Europe
      3. 4.6.3 APAC
        1. 4.6.3.1 China
        2. 4.6.3.2 India
        3. 4.6.3.3 Japan
        4. 4.6.3.4 South Korea
        5. 4.6.3.5 Malaysia
        6. 4.6.3.6 Thailand
        7. 4.6.3.7 Indonesia
        8. 4.6.3.8 Rest of APAC
      4. 4.6.4 South America
        1. 4.6.4.1 Brazil
        2. 4.6.4.2 Mexico
        3. 4.6.4.3 Argentina
        4. 4.6.4.4 Rest of South America
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC Countries
        2. 4.6.5.2 South Africa
        3. 4.6.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Moderna (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 BioNTech (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 CureVac (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Translate Bio (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Gritstone Oncology (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 eTheRNA (BE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 OncoOne (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Zymeworks (CA)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY CANCER TYPE
    6. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    7. 6.7 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    8. 6.8 CANADA MARKET ANALYSIS BY TECHNOLOGY
    9. 6.9 CANADA MARKET ANALYSIS BY APPLICATION
    10. 6.10 CANADA MARKET ANALYSIS BY CANCER TYPE
    11. 6.11 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    12. 6.12 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    13. 6.13 EUROPE MARKET ANALYSIS
    14. 6.14 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    15. 6.15 GERMANY MARKET ANALYSIS BY APPLICATION
    16. 6.16 GERMANY MARKET ANALYSIS BY CANCER TYPE
    17. 6.17 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    18. 6.18 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    19. 6.19 UK MARKET ANALYSIS BY TECHNOLOGY
    20. 6.20 UK MARKET ANALYSIS BY APPLICATION
    21. 6.21 UK MARKET ANALYSIS BY CANCER TYPE
    22. 6.22 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    23. 6.23 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    24. 6.24 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    25. 6.25 FRANCE MARKET ANALYSIS BY APPLICATION
    26. 6.26 FRANCE MARKET ANALYSIS BY CANCER TYPE
    27. 6.27 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    28. 6.28 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    29. 6.29 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    30. 6.30 RUSSIA MARKET ANALYSIS BY APPLICATION
    31. 6.31 RUSSIA MARKET ANALYSIS BY CANCER TYPE
    32. 6.32 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    33. 6.33 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    34. 6.34 ITALY MARKET ANALYSIS BY TECHNOLOGY
    35. 6.35 ITALY MARKET ANALYSIS BY APPLICATION
    36. 6.36 ITALY MARKET ANALYSIS BY CANCER TYPE
    37. 6.37 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    38. 6.38 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    39. 6.39 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    40. 6.40 SPAIN MARKET ANALYSIS BY APPLICATION
    41. 6.41 SPAIN MARKET ANALYSIS BY CANCER TYPE
    42. 6.42 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    43. 6.43 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    45. 6.45 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    46. 6.46 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
    47. 6.47 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    48. 6.48 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    49. 6.49 APAC MARKET ANALYSIS
    50. 6.50 CHINA MARKET ANALYSIS BY TECHNOLOGY
    51. 6.51 CHINA MARKET ANALYSIS BY APPLICATION
    52. 6.52 CHINA MARKET ANALYSIS BY CANCER TYPE
    53. 6.53 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    54. 6.54 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    55. 6.55 INDIA MARKET ANALYSIS BY TECHNOLOGY
    56. 6.56 INDIA MARKET ANALYSIS BY APPLICATION
    57. 6.57 INDIA MARKET ANALYSIS BY CANCER TYPE
    58. 6.58 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    59. 6.59 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    60. 6.60 JAPAN MARKET ANALYSIS BY TECHNOLOGY
    61. 6.61 JAPAN MARKET ANALYSIS BY APPLICATION
    62. 6.62 JAPAN MARKET ANALYSIS BY CANCER TYPE
    63. 6.63 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    64. 6.64 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    66. 6.66 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    67. 6.67 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
    68. 6.68 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    69. 6.69 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    70. 6.70 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    71. 6.71 MALAYSIA MARKET ANALYSIS BY APPLICATION
    72. 6.72 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
    73. 6.73 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    74. 6.74 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    75. 6.75 THAILAND MARKET ANALYSIS BY TECHNOLOGY
    76. 6.76 THAILAND MARKET ANALYSIS BY APPLICATION
    77. 6.77 THAILAND MARKET ANALYSIS BY CANCER TYPE
    78. 6.78 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    79. 6.79 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    80. 6.80 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    81. 6.81 INDONESIA MARKET ANALYSIS BY APPLICATION
    82. 6.82 INDONESIA MARKET ANALYSIS BY CANCER TYPE
    83. 6.83 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    84. 6.84 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    85. 6.85 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    86. 6.86 REST OF APAC MARKET ANALYSIS BY APPLICATION
    87. 6.87 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
    88. 6.88 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    89. 6.89 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    90. 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. 6.91 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    92. 6.92 BRAZIL MARKET ANALYSIS BY APPLICATION
    93. 6.93 BRAZIL MARKET ANALYSIS BY CANCER TYPE
    94. 6.94 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    95. 6.95 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    96. 6.96 MEXICO MARKET ANALYSIS BY TECHNOLOGY
    97. 6.97 MEXICO MARKET ANALYSIS BY APPLICATION
    98. 6.98 MEXICO MARKET ANALYSIS BY CANCER TYPE
    99. 6.99 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    100. 6.100 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    101. 6.101 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    102. 6.102 ARGENTINA MARKET ANALYSIS BY APPLICATION
    103. 6.103 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
    104. 6.104 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    105. 6.105 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
    109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    111. 6.111 MEA MARKET ANALYSIS
    112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
    115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
    120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    122. 6.122 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    123. 6.123 REST OF MEA MARKET ANALYSIS BY APPLICATION
    124. 6.124 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
    125. 6.125 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    126. 6.126 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. 6.128 RESEARCH PROCESS OF MRFR
    129. 6.129 DRO ANALYSIS OF HEALTHCARE
    130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. 6.133 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    134. 6.134 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    135. 6.135 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    136. 6.136 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    137. 6.137 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
    138. 6.138 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
    139. 6.139 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    140. 6.140 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    141. 6.141 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    142. 6.142 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.2.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.3.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.3.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.4.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.4.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.5.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.5.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.6.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.6.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.7.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.7.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.8.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.8.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.9.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.9.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.10.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.10.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.11.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.11.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.12.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.12.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.13.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.13.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.14.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.14.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.15.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.15.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.16.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.16.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.17.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.17.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.18.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.18.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.19.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.19.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.20.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.20.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.21.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.21.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.22.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.22.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.23.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.23.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.24.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.24.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.25.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.25.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.26.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.26.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.27.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.27.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.28.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.28.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.29.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.29.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.30.3 BY CANCER TYPE, 2025-2035 (USD Billion)
      4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      5. 7.30.5 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

mRNA Cancer Vaccines Therapeutics Market Segmentation

mRNA Cancer Vaccines Therapeutics Market By mRNA Cancer Vaccines Therapeutics Market (USD Billion, 2025-2035)

  • Self-Amplifying mRNA
  • Non-Self-Amplifying mRNA
  • Lipid Nanoparticle (LNP) Encapsulation

mRNA Cancer Vaccines Therapeutics Market By Application (USD Billion, 2025-2035)

  • Preventive Vaccines
  • Therapeutic Vaccines
  • Combination Therapies

mRNA Cancer Vaccines Therapeutics Market By Cancer Type (USD Billion, 2025-2035)

  • Melanoma
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer

mRNA Cancer Vaccines Therapeutics Market By Route of Administration (USD Billion, 2025-2035)

  • Intramuscular
  • Intravenous
  • Subcutaneous

mRNA Cancer Vaccines Therapeutics Market By Patient Demographics (USD Billion, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.